Institute for Colored Youth

Lifezone Metals Announces Two-Phased Development Plan for the Kabanga Nickel Project in Tanzania

Retrieved on: 
Monday, February 26, 2024

Lifezone Metals has determined that a two-phase development plan for its Kabanga Nickel Project will form the base case of the Definitive Feasibility Study.

Key Points: 
  • Lifezone Metals has determined that a two-phase development plan for its Kabanga Nickel Project will form the base case of the Definitive Feasibility Study.
  • The Company continues to collaborate closely with its project partner on this two-phased development plan, as well as numerous other Definitive Feasibility Study work streams.
  • Lifezone Metals is working to evolve and integrate sustainability across Project planning, implementation and in-country operational readiness.
  • Ongoing refinement of the development plan and metallurgical testing is aimed at maximizing the net present value of the Project while optimizing capital outlays.

Evolve Audit & Advisory Group joins Russell Bedford in South Africa

Retrieved on: 
Saturday, September 30, 2023

LONDON, Sept. 30, 2023 /PRNewswire-PRWeb/ -- Global professional services network, Russell Bedford International, has announced the appointment of Evolve Audit & Advisory Group as a network member firm in Bloemfontein, the capital and the largest city of the Free State province in South Africa.

Key Points: 
  • LONDON, Sept. 30, 2023 /PRNewswire-PRWeb/ -- Global professional services network, Russell Bedford International, has announced the appointment of Evolve Audit & Advisory Group as a network member firm in Bloemfontein, the capital and the largest city of the Free State province in South Africa.
  • Speaking about the appointment, Russell Bedford CEO, Stephen Hamlet, said: "I am delighted to welcome Evolve Audit & Advisory Group as an additional member firm in South Africa.
  • Stephen Fouchee, partner at Evolve Audit & Advisory Group, added: "Joining the Russell Bedford network is an exciting move for Evolve.
  • Emmanuel Dupeux, Russell Bedford global board director for EMEA, added: "I'm very pleased to welcome Evolve Audit & Advisory Group to our network in South Africa.

Farouk Khailann Joins Erez Capital as Venture Partner

Retrieved on: 
Wednesday, August 2, 2023

BOSTON, Aug 2, 2023 - (ACN Newswire) - Farouk Khailann, CEO of Premium Africa Holdings, Managing Partner of Akon Lighting and Strategic Advisor to the UAE Royal Family Office, Joins Erez Capital as Venture Partner.

Key Points: 
  • BOSTON, Aug 2, 2023 - (ACN Newswire) - Farouk Khailann, CEO of Premium Africa Holdings, Managing Partner of Akon Lighting and Strategic Advisor to the UAE Royal Family Office, Joins Erez Capital as Venture Partner.
  • Farouk Khailann is an African Entrepreneur with a strong commitment to Africa's economic growth.
  • We are lucky to have his leadership and to help the fund expand its footprint into these growing and dynamic markets," said Managing Partner and Founder of Erez Capital, Michael Benezra.
  • He works closely with the offices of five African presidents on various interventions geared towards the economic transformation of their respective countries.

The European Medicines Agency (EMA) Validated Regulatory Application for Arpraziquantel, a Potential Treatment for Schistosomiasis in Preschool-Aged Children

Retrieved on: 
Monday, January 23, 2023

Arpraziquantel, developed by the Pediatric Praziquantel Consortium, is a potential new treatment option tailored to improve child health by filling the treatment gap of an estimated 50 million preschool-aged children with schistosomiasis.

Key Points: 
  • Arpraziquantel, developed by the Pediatric Praziquantel Consortium, is a potential new treatment option tailored to improve child health by filling the treatment gap of an estimated 50 million preschool-aged children with schistosomiasis.
  • On behalf of the Pediatric Praziquantel Consortium, Merck submitted the regulatory application for arpraziquantel to the European Medicines Agency (EMA), which validated this application and started the scientific review process in December 2022.
  • Arpraziquantel represents the first investigational drug that has reached the regulatory phase amongst the portfolio of projects supported by GHIT Fund.
  • The drug praziquantel – the current standard treatment developed in the 1970s – is safe, effective and available for school-aged children and adults.